HNN3.0
Register
Register
Register

SAGITTA BIOTECH

Company (SME)

www.sagittabiotech.comLiège, Belgium
23 profile visits

About

Sagitta Biotech is developing innovative therapies against infectious diseases and cancer based on its viral vector/mRNA platform.

The technology allows us to develop very quickly vaccines that are safe and effective, but also to manufacture them at a very low cost (cents per dose) thanks to a "constant manufacturing process" (identical for all vaccines).

This allows us to get significant shortcuts during development, and reduce the cost of operations for our customers.

Representatives

CEO

SAGITTA BIOTECH

Marketplace (1)

  • Project cooperation

    Development of a vaccine against Tick-borne encephalitis virus

    Development of TBE vaccines based on Sagitta's vaccine backbone.

    • DESTINATION 3: HORIZON-HLTH-2026-01-DISEASE-04: Development of novel vaccines for viral pathogens with epidemic potential
    Author

    CEO at SAGITTA BIOTECH

    Liège, Belgium